BioLargo's Commercialization Partner Receives EPA Approval
SANTA ANA, CA - (NewMediaWire) - May 31, 2016 - BioLargo, Inc. (
"Effective and measurable control of pathogens in poultry operations is a priority for growers looking to protect their animals, especially in antibiotic-free lines," said Tom Bercaw, President of Clarion Water. "Use of an iSAN system to deliver metered IoMax provides effective sanitation with full automation, data logging and remote monitoring capabilities."
The active ingredient of IoMax™, free iodine, is well known for its efficacy as a broad-spectrum biocide across a wide variety of industries and applications. The iSAN system has the flexibility to deliver IoMax™ to provide beneficial supplementation to the animal diet with low levels of residual iodine when desired.
Clarion reports that state registrations for IoMax are still pending and it plans on pursuing additional approved uses in the near future.
Dennis Calvert, president of BioLargo, commented, "EPA approval for our iSAN related technology is a big step for our licensee and for BioLargo towards successful commercialization. It goes hand-in-hand with our efforts underway in Canada, where we plan for commercial trials with poultry processers, co-sponsored by the Alberta Poultry Growers Association, once the commercial prototype of our AOS Filter is finished. With the iSAN system, our AOS Filter, our award winning animal bedding products, and CupriDyne® Clean, we are building a complete suite of best-of-class products to make the production of poultry foods clean, safe and healthy. This is a great example of our commitment to 'Make Life Better' and it is an important milestone in our journey."
About BioLargo, Inc.
BioLargo, Inc. (
Safe Harbor Statement
The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, the risks and uncertainties included in BioLargo's current and future filings with the Securities and Exchange Commission, including those set forth in BioLargo's Annual Report on Form 10-K.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.